Finding the right route for insulin delivery – an overview of implantable pump therapy

References

• Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383:69–82.
   PubMed Web of Science ®Google Scholar
• Thabit H, Hovorka R. Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons. Expert Opin Drug Deliv. 2016;13:389–400.
   PubMed Web of Science ®Google Scholar
• Skyler JS. Continuous subcutaneous insulin infusion–an historical perspective. Diabetes Technol Ther. 2010;12(Suppl 1):S5–S9.
   PubMed Web of Science ®Google Scholar
• Blackshear PJ, Rohde TD, Grotting JC, et al. Control of blood glucose in experimental diabetes by means of a totally implantable insulin infusion device. Diabetes. 1979;28:634–639.
   PubMed Web of Science ®Google Scholar
• Point Study Group. One-year trial of a remote-controlled implantable insulin infusion system in type I diabetic patients.. Lancet. 1988; 2:866–869.
   PubMed Web of Science ®Google Scholar
• Selam JL, Micossi P, Dunn FL, et al. Clinical trial of programmable implantable insulin pump for type I diabetes. Diabetes Care. 1992;15:877–885.
   PubMed Web of Science ®Google Scholar
• Renard E, Schaepelynck-Bélicar P, Group E. Implantable insulin pumps. A position statement about their clinical use. Diabetes Metab. 2007;33:158–166.
   PubMed Web of Science ®Google Scholar
• Logtenberg SJ, Kleefstra N, Houweling ST, et al. Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial. Diabetes Care. 2009;32:1372–1377.
   PubMed Web of Science ®Google Scholar
• van Dijk PR, Logtenberg SJ, Groenier KH, et al. Continuous intraperitoneal insulin infusion in type 1 diabetes: a 6-year post-trial follow-up. BMC Endocr Disord. 2014;14:30.
   PubMed Web of Science ®Google Scholar
• van Dijk PR, Logtenberg SJ, Hendriks SH, et al. Intraperitoneal versus subcutaneous insulin therapy in the treatment of type 1 diabetes mellitus. Neth J Med. 2015;73:399–409.
   PubMed Web of Science ®Google Scholar
• Saudek CD, Selam JL, Pitt HA, et al. A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med. 1989;321:574–579.
   PubMed Web of Science ®Google Scholar
• Haveman JW, Logtenberg SJ, Kleefstra N, et al. Surgical aspects and complications of continuous intraperitoneal insulin infusion with an implantable pump. Langenbecks Arch Surg. 2010;395:65–71.
   PubMed Web of Science ®Google Scholar
• Brange J, Havelund S. Insulin pumps and insulin quality–requirements and problems. Acta Med Scand Suppl. 1983;671:135–138.
   PubMedGoogle Scholar
• Selam JL. Implantable insulin pumps. Lancet. 1999;354:178–179.
   PubMed Web of Science ®Google Scholar
• Grau U, Saudek CD. Stable insulin preparation for implanted insulin pumps. Laboratory and animal trials. Diabetes. 1987;36:1453–1459.
   PubMed Web of Science ®Google Scholar
• Schaepelynck P, Riveline JP, Renard E, et al. Assessment of a new insulin preparation for implanted pumps used in the treatment of type 1 diabetes. Diabetes Technol Ther. 2014;16:582–589.
   PubMed Web of Science ®Google Scholar
• Horwitz DL, Starr JI, Mako ME, et al. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest. 1975;55:1278–1283.
   PubMed Web of Science ®Google Scholar
• Song SH, McIntyre SS, Shah H, et al. Direct measurement of pulsatile insulin secretion from the portal vein in human subjects. J Clin Endocrinol Metab. 2000;85:4491–4499.
   PubMed Web of Science ®Google Scholar
• Sindelar DK, Balcom JH, Chu CA, et al. A comparison of the effects of selective increases in peripheral or portal insulin on hepatic glucose production in the conscious dog. Diabetes. 1996;45:1594–1604.
   PubMed Web of Science ®Google Scholar
• Herring R, Jones RH, Russell-Jones DL. Hepatoselectivity and the evolution of insulin. Diabetes Obes Metab. 2014;16:1–8.
   PubMed Web of Science ®Google Scholar
• Galassetti P, Chu CA, Neal DW, et al. A negative arterial-portal venous glucose gradient increases net hepatic glucose uptake in euglycemic dogs. Am J Physiol. 1999;277:E126–E134.
   PubMed Web of Science ®Google Scholar
• Edgerton DS, Lautz M, Scott M, et al. Insulin’s direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest. 2006;116:521–527.
   PubMed Web of Science ®Google Scholar
• Schade DS, Eaton RP, Friedman N, et al. The intravenous, intraperitoneal, and subcutaneous routes of insulin delivery in diabetic man. Diabetes. 1979;28:1069–1072.
   PubMed Web of Science ®Google Scholar
• Ruan Y, Thabit H, Leelarathna L, et al. Variability of insulin requirements over 12 weeks of closed-loop insulin delivery in adults with type 1 diabetes. Diabetes Care. 2016;39:1–3. DOI:10.2337/dc2315-2623
   Web of Science ®Google Scholar
• Schade DS, Eaton RP, Davis T, et al. The kinetics of peritoneal insulin absorption. Metabolism. 1981;30:149–155.
   PubMed Web of Science ®Google Scholar
• Gregory JM, Kraft G, Scott MF, et al. Insulin delivery into the peripheral circulation: a key contributor to hypoglycemia in type 1 diabetes. Diabetes. 2015;64:3439–3451.
   PubMed Web of Science ®Google Scholar
• Selam JL, Medlej R, M’bemba J, et al. Symptoms, hormones, and glucose fluxes during a gradual hypoglycaemia induced by intraperitoneal vs venous insulin infusion in type I diabetes. Diabet Med. 1995;12:1102–1109.
   PubMed Web of Science ®Google Scholar
• Ader M, Bergman RN. Peripheral effects of insulin dominate suppression of fasting hepatic glucose production. Am J Physiol. 1990;258:E1020–1032.
   PubMed Web of Science ®Google Scholar
• Giacca A, Fisher SJ, Shi ZQ, et al. Importance of peripheral insulin levels for insulin-induced suppression of glucose production in depancreatized dogs. J Clin Invest. 1992;90:1769–1777.
   PubMed Web of Science ®Google Scholar
• Oskarsson PR, Lins PE, Backman L, et al. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients. Diabetes Metab. 2000;26:118–124.
   PubMed Web of Science ®Google Scholar
• Satake S, Moore MC, Igawa K, et al. Direct and indirect effects of insulin on glucose uptake and storage by the liver. Diabetes. 2002;51:1663–1671.
   PubMed Web of Science ®Google Scholar
• Liebl A, Hoogma R, Renard E, et al. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion. Diabetes Obes Metab. 2009;11:1001–1008.
   PubMed Web of Science ®Google Scholar
• Hedman CA, Frystyk J, Lindström T, et al. Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion. Clin Endocrinol (Oxf). 2014;81:58–62.
   PubMed Web of Science ®Google Scholar
• Boering M, van Dijk PR, Logtenberg SJ, et al. Effects of intraperitoneal insulin versus subcutaneous insulin administration on sex hormone-binding globulin concentrations in patients with type 1 diabetes mellitus. Endocr Connect. 2016;5:136–142.
   PubMed Web of Science ®Google Scholar
• Selam JL, Kashyap M, Alberti KG, et al. Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites, and hormones in type I diabetes mellitus. Metabolism. 1989;38:908–912.
   PubMed Web of Science ®Google Scholar
• Duvillard L, Florentin E, Baillot-Rudoni S, et al. Comparison of apolipoprotein B100 metabolism between continuous subcutaneous and intraperitoneal insulin therapy in type 1 diabetes. J Clin Endocrinol Metab. 2005;90:5761–5764.
   PubMed Web of Science ®Google Scholar
• Ruotolo G, Micossi P, Galimberti G, et al. Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in type I diabetes. Metabolism. 1990;39:598–604.
   PubMed Web of Science ®Google Scholar
• Colette C, Pares-Herbute N, Monnier L, et al. Effect of different insulin administration modalities on vitamin D metabolism of insulin-dependent diabetic patients. Horm Metab Res. 1989;21:37–41.
   PubMed Web of Science ®Google Scholar
• Hanaire-Broutin H, Broussolle C, Jeandidier N, et al. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. A multicenter study. The EVADIAC Study Group. Evaluation dans le Diabète du Traitement par Implants Actifs. Diabetes Care. 1995;18:388–392.
   PubMed Web of Science ®Google Scholar
• Riveline JP, Vantyghem MC, Fermon C, et al. Subcutaneous insulin resistance successfully circumvented on long term by peritoneal insulin delivery from an implantable pump in four diabetic patients. Diabetes Metab. 2005;31:496–498.
   PubMed Web of Science ®Google Scholar
• DeVries JH, Snoek FJ, Kostense PJ, et al. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care. 2002;25:2074–2080.
   PubMed Web of Science ®Google Scholar
• Scavini M, Galli L, Reich S, et al. Catheter survival during long-term insulin therapy with an implanted programmable pump. The Implantable Insulin Pump Trial Study Group. Diabetes Care. 1997;20:610–613.
   PubMed Web of Science ®Google Scholar
• Selam JL, Raccah D, Jean-Didier N, et al. Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus intensive subcutaneous insulin therapy in type I diabetic patients. Diabetes Care. 1992;15:53–58.
   PubMed Web of Science ®Google Scholar
• Haardt MJ, Selam JL, Slama G, et al. A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes. Diabetes Care. 1994;17:847–851.
   PubMed Web of Science ®Google Scholar
• Schaepelynck P, Renard E, Jeandidier N, et al. A recent survey confirms the efficacy and the safety of implanted insulin pumps during long-term use in poorly controlled type 1 diabetes patients. Diabetes Technol Ther. 2011;13:657–660.
   PubMed Web of Science ®Google Scholar
• Gin H, Renard E, Melki V, et al. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. Diabetes Metab. 2003;29:602–607.
   PubMed Web of Science ®Google Scholar
• van Dijk PR, Logtenberg SJ, Groenier KH, et al. Complications of continuous intraperitoneal insulin infusion with an implantable pump. World J Diabetes. 2012;3:142–148.
   PubMedGoogle Scholar
• Renard E, Bringer J, Jacques-Apostol D, et al. Complications of the pump pocket may represent a significant cause of incidents with implanted systems for intraperitoneal insulin delivery. Diabetes Care. 1994;17:1064–1066.
   PubMed Web of Science ®Google Scholar
• Scavini M, Cristallo M, Sarmiento M, et al. Pump-pocket complications during long-term insulin delivery using an implanted programmable pump. Diabetes Care. 1996;19:384–385.
   PubMed Web of Science ®Google Scholar
• Chan SM, Chiu FK, Lam CW. Correlational study of the Chinese version of the executive interview (C-EXIT25) to other cognitive measures in a psychogeriatric population in Hong Kong Chinese. Int J Geriatr Psychiatry. 2006;21:535–541.
   PubMed Web of Science ®Google Scholar
• Renard E, Bouteleau S, Jacques-Apostol D, et al. Insulin underdelivery from implanted pumps using peritoneal route. Determinant role of insulin pump compatibility. Diabetes Care. 1996;19:812–817.
   PubMed Web of Science ®Google Scholar
• Jeandidier N, Boullu S, Busch-Brafin MS, et al. Comparison of antigenicity of Hoechst 21PH insulin using either implantable intraperitoneal pump or subcutaneous external pump infusion in type 1 diabetic patients. Diabetes Care. 2002;25:84–88.
   PubMed Web of Science ®Google Scholar
• Kessler L, Tritschler S, Bohbot A, et al. Macrophage activation in type 1 diabetic patients with catheter obstruction during peritoneal insulin delivery with an implantable pump. Diabetes Care. 2001;24:302–307.
   PubMed Web of Science ®Google Scholar
• Olsen CL, Chan E, Turner DS, et al. Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems. Diabetes Care. 1994;17:169–176.
   PubMed Web of Science ®Google Scholar
• Jeandidier N, Boivin S, Sapin R, et al. Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Diabetologia. 1995;38:577–584.
   PubMed Web of Science ®Google Scholar
• Liebl A, Frei T. Safety in continuous intraperitoneal insulin infusion CIPII via DiaPort (R): results from the DiaPort-001-study. Diabetologia. 2003;46:A46–A47.
   Web of Science ®Google Scholar
• Tauschmann M, Allen JM, Wilinska ME, et al. Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care. 2016. DOI:10.2337/dc16-1094
   Web of Science ®Google Scholar
• Thabit H, Tauschmann M, Allen JM, et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med. 2015;373:2129–2140.
   PubMed Web of Science ®Google Scholar
• Kropff J, Del Favero S, Place J, et al. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol. 2015;3:939–947.
   PubMed Web of Science ®Google Scholar
• Nimri R, Muller I, Atlas E, et al. MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care. 2014;37:3025–3032.
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316:1407–1408.
   PubMed Web of Science ®Google Scholar
• Renard E, Costalat G, Chevassus H, et al. Artificial beta-cell: clinical experience toward an implantable closed-loop insulin delivery system. Diabetes Metab. 2006;32:497–502.
   PubMed Web of Science ®Google Scholar
• Cengiz E, Bode B, Van Name M, et al. Moving toward the ideal insulin for insulin pumps. Expert Rev Med Devices. 2016;13:57–69.
   PubMed Web of Science ®Google Scholar
• Logtenberg SJ, Kleefstra N, Houweling ST, et al. Health-related quality of life, treatment satisfaction, and costs associated with intraperitoneal versus subcutaneous insulin administration in type 1 diabetes: a randomized controlled trial. Diabetes Care. 2010;33:1169–1172.
   PubMed Web of Science ®Google Scholar